October 17, 2014 News by Isaura Santos “MS Radio” Offers Multiple Sclerosis Patients Breaking News, Articles & Tips About the Disease Multiple Sclerosis information resourceĀ MSology.com has announced the launch ofĀ MS Radio, an exclusive MS-focused radio program, to celebrate the organization’s second anniversary. MSology.com provides news, feature articles and practical tips to more than 100,000 people worldwide. The first radio episode (available here) is a…
October 9, 2014 News by Patricia Silva, PhD New Long-lasting Multiple Sclerosis Drug Will Come At a Steep Price Now more than ever, groundbreaking, new therapies for chronic diseases and infections come with high price tags. Earlier in the year, Gilead Sciences’ drugĀ Sovaldi for Hepatitis C, as well as Vertex’s Kalydeco for Cystic Fibrosis, both raised eyebrows over their cost. Now, a new MS therapy is doing the…
October 3, 2014 News by Patricia Inacio, PhD 159 New Multiple Sclerosis Genetic Variations Discovered By Researchers Approximately 110 multiple genetic variationsĀ were previously identified by genome-wide association studies (GWAS) to be associated with Multiple Sclerosis (MS). Now, that number has increased, with more than 159 genetic variants identified, thanks to new research presented by Philip De Jager, M.D., of Brigham and Womenās Hospital, Harvard Medical…
September 16, 2014 News by Patricia Silva, PhD Biogen’s Two-Year Study Confirms Plegridy’s Efficacy and Safety as Relapsing MS Treatment Biogen Idec revealed data from itsĀ second year of the phase 3 ADVANCE clinical trial for the study of Plegridy as a treatment for patients with relapsing forms of multiple sclerosis, which demonstrated the positive effects of the subcutaneous injectable therapyĀ beyond the first year…
September 16, 2014 News by Patricia Silva, PhD Merck Serono Awards ā¬1 Million at the Second Annual Grant for Multiple Sclerosis Innovation Biopharmaceutical companyĀ Merck Serono, a division of Merck, recently awardedĀ a total of ā¬1 million to the five winners of theĀ second annual Grant for Multiple Sclerosis Innovation (GMSI) at MS Boston 2014, the joint meeting of the Americas Committee for Treatment and Research in MS (ACTRIMS) and European Committee…
September 15, 2014 News by Patricia Silva, PhD Biogen Idec’s Study Reviews Positive Results Over Five Years of Tecfidera RRMS Treatment Biogen Idec presented theĀ five-year results from its ENDORSE phase 3 extension study of TecfideraĀ (dimethyl fumarate), which revealed that the treatment is able to provide strong and sustained efficacy to patients with relapsing-remitting multiple sclerosis (RRMS), at last week’sĀ ACTRIMS-ECTRIMSĀ summit. Not only did…
September 12, 2014 News by Patricia Silva, PhD Novartis Presents Impressive Gilenya Updates at MSBoston 2014 This past Wednesday, September 10th, the largest, most anticipated multiple sclerosis (MS) convention — the 6th Joint ACTRIMS-ECTRIMS Triennial Meeting, MSBoston 2014 — kicked off with a whopping 8,000 registered attendees, all eager to learn more about the latest developments in MS. One of the highlights of the event…
September 12, 2014 News by Patricia Silva, PhD EMD Serono’s Multiple Sclerosis Pipeline On Display at 2014 ACTRIMS-ECTRIMS Meeting in Boston During the joint meeting of the Americas Committee for Treatment and Research in MS (ACTRIMS) and European Committee for Treatment and Research in MS (ECTRIMS), taking place in Boston from September 10-13, EMD Serono, Inc., a subsidiary of Merck KGaA, will present new data from its multiple sclerosis…
September 12, 2014 News by Maureen Newman Real-World Analysis of AMPYRA Multiple Sclerosis Drug Presented by Acorda and HealthCore Acorda Therapeutics will present results of a study analyzing AMPYRA (dalfampridine) Extended Release Tablets in multiple sclerosis patients at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston, held through September 10-13. Unlike many other studies of therapeutic agents, this study looked at prescribing patterns, patient compliance, and budget impact…
September 11, 2014 News by Patricia Silva, PhD Receptos to Present Data on RMS Treatment Trial at MSBoston 2014 Biopharmaceutical companyĀ Receptos, Inc. announced that they will review data from the phase 2 portion of theĀ RADIANCE trial,Ā the company’s phase 2 / 3 study testing RPC1063 in the treatment ofĀ Relapsing Multiple Sclerosis (RMS).Ā The data is being presented at theĀ largest meeting dedicated to multiple sclerosis…
September 10, 2014 News by Patricia Silva, PhD Largest Multiple Sclerosis Conference Begins in Boston; 8,000 Attendees Expected See below for the complete schedule for this year’sĀ ACTRIMS-ECTRIMS Multiple Sclerosis conference in Boston, and stay tuned to Multiple Sclerosis News throughout the week for continuing coverage on breaking science and research news for MS. For the past few weeks, Multiple Sclerosis News Today has been following the lead-up…
September 9, 2014 News by Patricia Silva, PhD Genzyme’s Aubagio, Lemtrada MS Therapies To Showcase at Conference During the 30th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) taking place in Boston between September 10th and 13th, Genzyme, a Sanofi company, will present its multiple sclerosis (MS) pipeline with a new group of trial treatments for early development of MS.
September 9, 2014 News by Patricia Silva, PhD Large Multiple Sclerosis Product Update To Be Presented By Biogen Biogen Idec, one of the first true biotech companies specializing in products indicated forĀ neurodegenerative diseases, hematologic conditions, and autoimmune disorders, is preparing to present over 90 poster presentations during this week’s 6th Joint ACTRIMS-ECTRIMS Meeting. The event is scheduled to take place from Wednesday, September 10th through Saturday the…
September 8, 2014 News by Patricia Silva, PhD Novartis to Present New Gilenya Data at ACTRIMS-ECTRIMS Meeting Those attending this week’sĀ ACTRIMS-ECTRIMSĀ conventionĀ set to take place on the 10th of September until the 13th in Boston, can expect Swiss pharmaceutical companyĀ NovartisĀ to present promising findings on Gilenya (fingolimod)Ā — the company’s leading oral formulation for relapsing-remitting multiple sclerosis (RRMS). In previously completed studies and clinical trials,…
September 3, 2014 News by Patricia Silva, PhD Importance of Brain Shrinkage for MS Treatment Measure Focus of Novartis Presentation Novartis has announced that it will present new analyses and redefinedĀ treatment goals for multiple sclerosis (MS) at theĀ 2014 Joint Americas and European Committees for Treatment and Research in Multiple Sclerosis Meeting (ACTRIMS-ECTRIMS), which is taking place in Boston, between September 10 and 13. Novartis claims to have…
June 16, 2014 News by Patricia Silva, PhD Researcher Recommends Brain Imaging To Treat MS-Related Depression Magnetic resonance imaging (MRI) can predict responses to depression treatment in patients with multiple sclerosis (MS), according to Anthony Feinstein, Professor at the Department of Psychiatry of the Sunnybrook Health Sciences Centre & the University of Toronto. In the presentation āDepression in MS: Is brain imaging helpful?ā at this…